{
  "type": "hyp",
  "text": "Treatment of a T-lymphocytic cell line with micromolar concentrations of HOCl promoted the appearance of transcription factor NF-kappaB (the heterodimeric p50/p65 heterodimer) in the nucleus of the cells even in the absence of de novo protein synthesis.\n",
  "self": {
    "NER": {
      "answers": [],
      "QG_hash=ThomasNLG/t5-qg_squad1-en": {
        "questions": []
      }
    },
    "NOUN": {
      "answers": [
        "Treatment",
        "a T-lymphocytic cell line",
        "micromolar concentrations",
        "HOCl",
        "the appearance",
        "transcription factor NF-kappaB",
        "the heterodimeric p50/p65 heterodimer",
        "the nucleus",
        "the cells",
        "the absence",
        "de novo protein synthesis"
      ],
      "QG_hash=ThomasNLG/t5-qg_squad1-en": {
        "questions": [
          "What promoted the appearance of transcription factor NF-kappaB?",
          "What type of cell was treated with micromolar concentrations of HOCl?",
          "What was used to promote the appearance of NF-kappaB?",
          "What substance was used to promote the appearance of NF-kappaB?",
          "What did treatment of a T-lymphocytic cell line with micromolar",
          "What is the heterodimeric p50/p65 heterodimer?",
          "What is NF-kappaB?",
          "Where did the NF-kappaB appear?",
          "Where did NF-kappaB appear in the nucleus of cells?",
          "In what condition did the NF-kappaB appear in the nucleus of",
          "What did the treatment of a T-lymphocytic cell line with microm"
        ]
      }
    }
  },
  "asked": {
    "What promoted the appearance of transcription factor NF-kappaB in the nucleus": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "Treatment of a T-lymphocytic cell line with micromolar concentrations",
        "answerability": 0.6904934048652649,
        "ground_truth": {
          "Treatment": {
            "bertscore": 0.6724782586097717,
            "f1": 0.2222222222222222
          }
        }
      }
    },
    "What type of cell was treated with micromolar concentrations of HOCl?": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "T-lymphocytic",
        "answerability": 0.9954196810722351,
        "ground_truth": {
          "a T-lymphocytic cell line": {
            "bertscore": 0.8892152309417725,
            "f1": 0.5
          }
        }
      }
    },
    "What was used to promote the appearance of NF-kappaB?": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "HOCl",
        "answerability": 0.9485629200935364,
        "ground_truth": {
          "micromolar concentrations": {
            "bertscore": 0.6637406945228577,
            "f1": 0
          }
        }
      }
    },
    "What substance was used to promote the appearance of NF-kappaB?": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "HOCl",
        "answerability": 0.9807767868041992,
        "ground_truth": {
          "HOCl": {
            "bertscore": 1.0000003576278687,
            "f1": 1.0
          }
        }
      }
    },
    "What did treatment of a T-lymphocytic cell line with micromolar": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "unanswerable",
        "answerability": 0.6442861557006836,
        "ground_truth": {
          "the appearance": {
            "bertscore": 0.6999255418777466,
            "f1": 0
          }
        }
      }
    },
    "What is the heterodimer p50/p65?": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "transcription factor NF-kappaB",
        "answerability": 0.9850760102272034,
        "ground_truth": {
          "transcription factor NF-kappaB": {
            "bertscore": 0.9999997615814209,
            "f1": 1.0
          }
        }
      }
    },
    "What is the transcription factor NF-kappaB?": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "the heterodimeric p50/p65 heterodimer",
        "answerability": 0.9815158247947693,
        "ground_truth": {
          "(the heterodimer p50/p65": {
            "bertscore": 0.8791473507881165,
            "f1": 0.8
          }
        }
      }
    },
    "Where did the NF-kappaB appear?": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "in the nucleus",
        "answerability": 0.9366648197174072,
        "ground_truth": {
          "the nucleus": {
            "bertscore": 0.8861324787139893,
            "f1": 0.6666666666666666
          }
        }
      }
    },
    "Where did the NF-kappaB appear in the nucleus of cells?": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "unanswerable",
        "answerability": 0.3002853989601135,
        "ground_truth": {
          "the cells": {
            "bertscore": 0.662919282913208,
            "f1": 0
          }
        }
      }
    },
    "In what condition did the NF-kappaB appear in the nucleus of": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "unanswerable",
        "answerability": 0.2651241421699524,
        "ground_truth": {
          "the absence": {
            "bertscore": 0.6903127431869507,
            "f1": 0
          }
        }
      }
    },
    "What did the treatment of a T-lymphocytic cell line with microm": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "unanswerable",
        "answerability": 0.5678291916847229,
        "ground_truth": {
          "de novo protein synthesis": {
            "bertscore": 0.647691011428833,
            "f1": 0
          }
        }
      }
    }
  }
}